Shionogi & Co., Ltd.
[Shionogi & Co., Ltd.] Additional Approval for Pediatric Use of COVID-19 Treatment | June 2026
Shionogi & Co., Ltd. has obtained approval for an expanded pediatric dose and administration method of the anti-SARS-CoV-2 drug Zocova, extending its application to children aged 6 to under 12 years old weighing at least 20kg. Safety and blood concentration levels have been confirmed, broadening treatment options for COVID-19.
Key Figures
- Approved pediatric application: age 6 to under 12 years, weighing at least 20kg
- Addition of new 25mg tablet approval
- Number of domestic Phase 3 clinical trial registrations: 117 cases
AI要約
Overview of Business Performance
This document does not present Shionogi & Co., Ltd.'s financial results but provides information on the newly approved expanded pediatric use of the anti-COVID-19 drug Zocova. Based on results from domestic Phase 3 clinical trials, safety and blood concentration levels have been confirmed, leading to the approval of a new 25mg tablet for children aged 6 and above but under 12 years old weighing at least 20kg. This expansion increases treatment options for COVID-19 and allows use regardless of the risk of severe illness.
Future Outlook and Impact
This approval represents a significant advancement in addressing public health challenges posed by COVID-19 and is part of Shionogi & Co., Ltd.'s efforts to promote comprehensive infectious disease care. Going forward, the company will continue to rapidly develop treatments and vaccines tailored to emerging variants and seasonal trends. The impact on consolidated performance for the fiscal year ending March 2027 is expected to be minimal.
Shionogi & Co., Ltd.
Company overview · Stock price · Financial data · All IR
